IL257444D0 - Fumagillol spirocyclic compounds and fused bicyclic compounds and their use as metap2 inhibitors - Google Patents

Fumagillol spirocyclic compounds and fused bicyclic compounds and their use as metap2 inhibitors

Info

Publication number
IL257444D0
IL257444D0 IL257444A IL25744418A IL257444D0 IL 257444 D0 IL257444 D0 IL 257444D0 IL 257444 A IL257444 A IL 257444A IL 25744418 A IL25744418 A IL 25744418A IL 257444 D0 IL257444 D0 IL 257444D0
Authority
IL
Israel
Prior art keywords
compounds
fumagillol
use
fused bicyclic
spirocyclic
Prior art date
Application number
IL257444A
Other languages
Hebrew (he)
Inventor
Robert Zahler
James E Vath
Zhenwei Cai
Zhixing Wu
Original Assignee
Zafgen Inc
Robert Zahler
James E Vath
Zhenwei Cai
Zhixing Wu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201510490559.1A priority Critical patent/CN106432255A/en
Priority to US201562210102P priority
Priority to PCT/US2016/046515 priority patent/WO2017027687A1/en
Application filed by Zafgen Inc, Robert Zahler, James E Vath, Zhenwei Cai, Zhixing Wu filed Critical Zafgen Inc
Publication of IL257444D0 publication Critical patent/IL257444D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring heteroatom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/04Compounds containing oxirane rings containing only hydrogen and carbon atoms in addition to the ring oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
IL257444A 2015-08-11 2018-02-08 Fumagillol spirocyclic compounds and fused bicyclic compounds and their use as metap2 inhibitors IL257444D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201510490559.1A CN106432255A (en) 2015-08-11 2015-08-11 Fumigillol spiro-compound, preparation and use method thereof
US201562210102P true 2015-08-26 2015-08-26
PCT/US2016/046515 WO2017027687A1 (en) 2015-08-11 2016-08-11 Fumagillol spirocyclic compounds and fused bicyclic compounds and their use as metap2 inhibitors

Publications (1)

Publication Number Publication Date
IL257444D0 true IL257444D0 (en) 2018-04-30

Family

ID=57983740

Family Applications (1)

Application Number Title Priority Date Filing Date
IL257444A IL257444D0 (en) 2015-08-11 2018-02-08 Fumagillol spirocyclic compounds and fused bicyclic compounds and their use as metap2 inhibitors

Country Status (12)

Country Link
US (4) US20180237449A1 (en)
EP (1) EP3334729A1 (en)
JP (1) JP2018522930A (en)
KR (1) KR20180035909A (en)
CN (2) CN106432255A (en)
AU (1) AU2016306561A1 (en)
CA (1) CA2995369A1 (en)
EA (1) EA201890448A1 (en)
IL (1) IL257444D0 (en)
MX (1) MX2018001735A (en)
PH (1) PH12018500316A1 (en)
WO (1) WO2017027687A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013169860A1 (en) 2012-05-09 2013-11-14 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
WO2018148652A1 (en) * 2017-02-10 2018-08-16 Zafgen, Inc. Methods for identifying metap-2 modulators

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164410A (en) 1988-01-09 1992-11-17 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
PH26256A (en) 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
AT150750T (en) 1988-09-01 1997-04-15 Takeda Chemical Industries Ltd Fumagillol derivatives
US5180738A (en) 1988-09-01 1993-01-19 Takeda Chemical Industries Fumagillol derivatives and pharmaceutical compositions thereof
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
DE69001187T2 (en) 1989-03-06 1993-07-08 Takeda Chemical Industries Ltd 6-epifumagillole, their production and their use.
US5288722A (en) 1989-03-06 1994-02-22 Takeda Chemical Industries, Ltd. 6-amino-6-desoxyfumagillols, production and use thereof
US5290807A (en) 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
US6017954A (en) 1989-08-10 2000-01-25 Children's Medical Center Corp. Method of treating tumors using O-substituted fumagillol derivatives
EP0415294A3 (en) 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
TW282399B (en) 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
DE69330690T2 (en) 1992-01-30 2002-06-20 Takeda Chemical Industries Ltd A process for producing highly water-soluble Zyklodextrinkomplexe
DE69311278D1 (en) 1992-12-16 1997-07-10 Takeda Chemical Industries Ltd Stable pharmaceutical preparation Fumagillolderivaten
EP0817626B1 (en) 1995-03-27 1998-10-28 Assistance Publique, Hopitaux De Paris Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
WO1997013509A1 (en) 1995-10-11 1997-04-17 Fujisawa Pharmaceutical Co., Ltd. Vascular permeation inhibitor
EP0799616A1 (en) 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
AU3968597A (en) 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
US6281245B1 (en) 1996-10-28 2001-08-28 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
US6207704B1 (en) 1997-06-09 2001-03-27 Massachusetts Institute Of Technology Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
AU3352799A (en) 1997-10-31 1999-08-23 Children's Medical Center Corporation Method for regulating size and growth of vascularized normal tissue
US6242494B1 (en) 1998-05-01 2001-06-05 Abbott Laboratories Substituted β-amino acid inhibitors of methionine aminopeptidase-2
KR100357541B1 (en) 1998-05-15 2002-10-08 주식회사종근당 5-Demthoxyfumagillol derivatives and processes for preparing the same
KR100357542B1 (en) 1998-05-15 2002-10-08 주식회사종근당 Fumagillol derivatives and preparation method thereof
US6277391B1 (en) 1998-06-05 2001-08-21 Samyang Corporation Composition and method of treating diseases and disorders of the prostate
JP2000116337A (en) 1998-10-09 2000-04-25 Nippon Shokuhin Kako Co Ltd Pet food
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
YU74701A (en) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Tri-aryl acid derivatives as ppar receptor ligands
AU7989400A (en) 1999-10-01 2001-05-10 Smithkline Beecham Corporation Compounds and methods
JP2003530438A (en) 2000-04-12 2003-10-14 スミスクライン・ビーチャム・コーポレイション Compounds and methods
US6323228B1 (en) 2000-09-15 2001-11-27 Abbott Laboratories 3-substituted indole angiogenesis inhibitors
AR030631A1 (en) 2000-09-29 2003-08-27 Abbott Lab Antiangiogenic polypeptides and methods for inhibiting angiogenesis
EP1330447A2 (en) 2000-11-01 2003-07-30 Praecis Pharmaceuticals Incorporated Peptides as met-ap2 inhibitors
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
EP1379241A1 (en) 2001-03-29 2004-01-14 SmithKline Beecham Corporation Compounds and methods
US20020183242A1 (en) 2001-04-11 2002-12-05 Jack Henkin Peptide antiangiogenic drugs
US7087768B2 (en) 2001-09-27 2006-08-08 Equispharm Co., Ltd. Fumagillol derivatives and preparing method thereof
US6803382B2 (en) 2001-11-09 2004-10-12 Galderma Research & Development, S.N.C. Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
KR100451485B1 (en) 2002-03-28 2004-10-06 주식회사종근당 Inclusion compounds of fumagillol derivative or its salt, and pharmaceutical compositions comprising the same
AU2003243604A1 (en) 2002-06-12 2003-12-31 Silicon Optix, Inc. Automatic keystone correction system and method
US6989392B2 (en) 2002-06-18 2006-01-24 Abbott Laboratories 2-Aminoquinolines as melanin concentrating hormone receptor antagonists
US7030262B2 (en) 2002-08-06 2006-04-18 Abbott Laboratories 3-Amino-2-hydroxyalkanoic acids and their prodrugs
US20040067266A1 (en) 2002-10-07 2004-04-08 Toppo Frank R. Weight loss compound
US20040157836A1 (en) 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
US7491718B2 (en) 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
US20040204472A1 (en) 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
CN1902215A (en) 2003-12-29 2007-01-24 普雷西斯药品公司 Inhibitors of methionine aminopeptidase-2 and uses thereof
KR100552043B1 (en) 2004-02-28 2006-02-20 주식회사종근당 Composition for obesity treatment comprising fumagillol derivatives
RU2007103178A (en) 2004-06-30 2008-08-10 Комбинаторкс, Инкорпорейтед (Us) Methods and reagents for the treatment of metabolic disorders
WO2006010498A2 (en) 2004-07-28 2006-02-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with methionine aminopeptidase 2 (metap2)
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
EP1841761A4 (en) 2005-01-26 2008-10-29 Chong Kun Dang Pharm Corp Fumagillol derivatives or method for preparation of fumagillol derivatives, and pharmaceutical compositions comprising the same
FR2886855B1 (en) 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Use of fumagillin and its derivatives to increase the bioavailability of the macrocyclic lactones
WO2006138475A2 (en) 2005-06-16 2006-12-28 Jenrin Discovery Mao-b inhibitors useful for treating obesity
EP2170402B1 (en) 2007-06-26 2015-03-25 Children's Medical Center Corporation Metap-2 inhibitor polymersomes for therapeutic administration
EA020251B1 (en) 2007-11-28 2014-09-30 Мерсана Терапьютикс, Инк. Biocompatible biodegradable fumagillin analog conjugates
WO2010009374A1 (en) 2008-07-18 2010-01-21 Zafgen, Inc. Methods of treating an overweight or obese subject
EP2350012B1 (en) 2008-10-06 2017-06-28 The Johns Hopkins University Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
CA2741683C (en) 2008-10-24 2016-03-22 Wake Forest University Platinum acridine anti-cancer compounds and methods thereof
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2010065879A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
WO2010065881A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
WO2010065877A2 (en) * 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
EP2486004B1 (en) 2009-10-09 2017-05-03 Zafgen, Inc. Sulphone compounds for use in the treatment of obesity
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
MX343135B (en) 2010-01-08 2016-10-25 Zafgen Corp * Fumagillol type compounds and methods of making and using same.
US20130023513A1 (en) 2010-01-12 2013-01-24 Hughes Thomas E Methods and Compositions for Treating Cardiovascular Disorders
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
WO2011150338A1 (en) 2010-05-27 2011-12-01 Zafgen Corporation Methods of treating obesity
JP5913310B2 (en) 2010-07-22 2016-04-27 ザフゲン,インコーポレイテッド Tricyclic compounds and methods of making and using the same
WO2012051318A1 (en) 2010-10-12 2012-04-19 Zafgen Corporation Sulphonamide compounds and methods of making and using same
MX2013005208A (en) 2010-11-09 2013-08-01 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same.
US20140073691A1 (en) 2010-11-10 2014-03-13 Zafgen, Inc. Methods and composition for Treating Thyroid Hormone Related Disorders
US20130316994A1 (en) 2010-11-29 2013-11-28 Zafgen, Inc. Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors
US20140011870A1 (en) 2010-11-29 2014-01-09 Zafgen, Inc. Methods of Treating Obesity Using an Effective Dose of a METAP-2 Inhibitor
KR20140009273A (en) 2010-11-29 2014-01-22 자프겐 인크. Treatment of obesity using non-daily administration of 6-0-(4-dimethylaminoethoxy) cinnamoyl fumagillol
EP2668169B1 (en) 2011-01-26 2017-11-15 Zafgen, Inc. Tetrazole compounds and methods of making and using same
US9328082B2 (en) 2011-03-08 2016-05-03 Zafgen, Inc. Oxaspiro[2.5]octane derivatives and analogs
KR20140053013A (en) 2011-05-06 2014-05-07 자프겐 인크. Tricyclic sulfonamide compounds and methods of making and using same
KR101979039B1 (en) 2011-05-06 2019-05-15 자프겐 인크. Partially saturated tricyclic compounds and methods of making and using same
CN103764652B (en) 2011-05-06 2016-03-23 扎夫根股份有限公司 Pyrazole tricyclic sulfonamide compounds and their preparation and use
US9090640B2 (en) 2011-09-02 2015-07-28 Ulrich Bierbach Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
JP2015509102A (en) 2012-01-18 2015-03-26 ザフゲン,インコーポレイテッド Tricyclic sulfone compounds and methods for making and using the same
AU2013209723B2 (en) 2012-01-18 2016-11-24 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
MX2014013525A (en) 2012-05-07 2015-10-22 Zafgen Inc Polymorphic salt of the oxalate salt of 6 - o - ( 4 - dimethylaminoethoxy) cinnarnoyl fumagillol and methods of making and using same.
KR20150013222A (en) 2012-05-08 2015-02-04 자프겐 인크. Treating hypothalamic obesity with metap2 inhibitors
WO2013169860A1 (en) * 2012-05-09 2013-11-14 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
WO2014169026A1 (en) * 2013-04-10 2014-10-16 Syndevrx, Inc. Metap2 inhibitors and methods of treating obesity
AR105671A1 (en) 2015-08-11 2017-10-25 Zafgen Inc Heterocyclic compounds of fumagillol and its methods of making and using

Also Published As

Publication number Publication date
CN106432255A (en) 2017-02-22
AU2016306561A1 (en) 2018-03-01
KR20180035909A (en) 2018-04-06
MX2018001735A (en) 2018-09-06
US20190092781A1 (en) 2019-03-28
US20180237449A1 (en) 2018-08-23
PH12018500316A1 (en) 2018-08-13
US20180079737A1 (en) 2018-03-22
US20190023716A1 (en) 2019-01-24
EA201890448A1 (en) 2018-10-31
JP2018522930A (en) 2018-08-16
CN108349954A (en) 2018-07-31
CA2995369A1 (en) 2017-02-16
US9944613B2 (en) 2018-04-17
EP3334729A1 (en) 2018-06-20
WO2017027687A1 (en) 2017-02-16

Similar Documents

Publication Publication Date Title
RU2017123539A (en) Calibrated dose control
SG10201710705UA (en) Novel bicyclic bromodomain inhibitors
RS59059B1 (en) Diaryl macrocycles as modulators of protein kinases
IL246902D0 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
RU2017106027A (en) Absorbent articles containing channels of various configurations
RU2017125025A (en) Condensed ring heteroarryl compounds and their application as trk inhibitors
RU2017111888A (en) Triazolopyrazinones as pde1 inhibitors
SG11201706287PA (en) Bicyclic heterocycles as fgfr inhibitors
RU2016137744A (en) Compositions of polymers for non-laceral stimulation
PL3228647T3 (en) Polycarbonate resin composition
IL250579D0 (en) Cd73 blockade
IL253869D0 (en) Bicyclic heterocycles as fgfr4 inhibitors
RU2015128342A (en) sound absorber
IL257026D0 (en) Solid state forms of eluxadoline
PL3207043T3 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
RU2017126717A (en) Application of picolinamides as fungicides
RU2017114352A (en) ANTAGONISTS INTEGRINE ανβ6
RU2016137174A (en) Absorbent articles containing zones
IL246575D0 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
IL247289D0 (en) Use of 3-isoxazolidinones compounds as selective herbicides
EP3240418A4 (en) Use of macrocyclic picolinamides as fungicides
EP3227281A4 (en) Substituted pyridinones as bromodomain inhibitors
IL252756D0 (en) Solid forms of an ask1 inhibitor
EP3230277A4 (en) Substituted heterocycles as bromodomain inhibitors
GB201805907D0 (en) Mitigation of anti-sandbox malware techniques